Products
Indatuximab Ravtansine Biosimilar Antibody-Drug Conjugate (CD138) for Research
Pre-made Indatuximab Ravtansine benchmark antibody (Whole mAb ADC, anti-SDC1 therapeutic antibody, Anti-CD138/SDC/SYND1/syndecan Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Indatuximab ravtansine (BT62) is an immunomodulator and antineoplastic antibody-drug conjugate.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-865-1mg | 1mg | |
| GMP-Bios-INN-865-10mg | 10mg | |
| GMP-Bios-INN-865-100mg | 100mg | |
| GMP-Bios-INN-865-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Indatuximab Ravtansine Biosimilar, Whole Mab Adc, Anti-Sdc1 Antibody: Anti-CD138/SDC/SYND1/syndecan therapeutic antibody Drug Conjugate |
| INN Name | Indatuximab Ravtansine |
| Target | SDC1 |
| Format | Whole mAb ADC |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG4 - kappa |
| VD LC | IgG4 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | ImmunoGen Inc. (Cambridge MA USA) / Biotest AG (Dreieich Germany) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - SDC1
1. Protein Syndecan-1
2. Gene SDC1
3. Organism Homo sapiens (Human)
Function
Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413).
